Read this message on another board. Allow me to share.
james08099 • Oct 21, 2013 12:00 PM Flag
0users liked this postsusers disliked this posts1Reply
RAJ! Check out CYTK it is the next ACAD
CYTK presents the same misunderstanding as ACAD. ACAD, if anyone remembers failed their first phase three bc the 10mg and the 40 mg pimavaserin were combined in the same study, but it was only the 40 mg dosage that had a effect on the very sick Parkinson's patients. That misunderstanding caused acad to plummet under $1, until the second phase 3 trial was preformed. Like ACAD, CYTK has a drug that is more effective at a higher dosage and when the lower doses are cut from the phase 3 study, it will show significance. It is these misunderstandings that create opportunities. Been in Rockwell since $3 with Raj and ACAD at $2. This is the next one to move. Everyone should check it out Less